Whole brain volume change over 5 years using the SIENA pipeline. by Renxin Chu (5169857)

Multivariable Linear Regression Model of the Residents P-V Fit score^a. by Yaotian Fan (5917766)

Subjects:

Descriptive statistics (mean [standard deviation] or % [sample size]) for study variables analyzed in the current study. by Angelina R. Sutin (9216456)

Baseline clinical profile of hospitalized COVID-19 patients with low and high renalase. by Basmah Safdar (12213257)

Flow chart of study patients from all COVID-19 admissions to the institution from March to July 2020. by Basmah Safdar (12213257)

Geometric mean concentrations of 5 most abundant PCDD/F congeners and the sum of other congeners (A), and PCDD and PCDF TEQ (C) in different study areas during the first (1972–1986... by Matti Viluksela (321291)

Inner medullary expression of the V2 vasopressin receptor. by Sophie Constantin Lütken (689916)

Effects of FE and RUD wrist postures on the mean shape signature phase shift within each quartile. by Drew A. Anderson (14197446)

Subjects:

Exposures to PM_2.5, PM₁₀ and Nitrogen dioxide. by Chika Edward Uzoigwe (20460686)

“…A sizeable proportion also had annual mean exposures that surpassed the WHO PM₁₀ (14.8%) and nitrogen dioxide (63%) recommended thresholds. …”

BH3 Peptides induces a decrease in mitochondrial membrane potential but does not engage the Permeability Transition Pore. by Emelyn H. Shroff (163459)

Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Population changes of <i>M</i>. <i>bavaricum</i> (a) and cocci (b) in Earth’s field (red symbols), zero field (black symbols) and alternating field (blue symbols) as a function of... by Xuegang Mao (599968)

Subjects:

ASO treatment suppresses the palbociclib-mediated induction of MEG3 and decrease in cell proliferation in A549 cells. by Traci L. Kruer (3342425)

Dexamethasone (DEX)-induced transient <i>CPK31</i> expression caused a decrease in As(III) tolerance. by Ruijie Ji (3839032)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects: